| Drug General Information |
| Drug ID |
D0MS3Z
|
| Former ID |
DNC002344
|
| Drug Name |
GSK690693
|
| Drug Type |
Small molecular drug
|
| Indication |
Hematologic malignancies [ICD9: 200-209; ICD10:C81-C86]
|
Phase 1 |
[1],
[2]
|
|---|
| Therapeutic Class |
Anticancer Agents
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C21H27N7O3
|
| InChI |
InChI=1S/C21H27N7O3/c1-4-28-18-15(30-12-13-6-5-9-23-10-13)11-24-14(7-8-21(2,3)29)16(18)25-20(28)17-19(22)27-31-26-17/h11,13,23,29H,4-6,9-10,12H2,1-3H3,(H2,22,27)/t13-/m0/s1
|
| InChIKey |
KGPGFQWBCSZGEL-ZDUSSCGKSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
26681942, 46135378, 46563378, 56310458, 56374157, 103604655, 125329936, 126626056, 131480689, 134346155, 135597634, 136340166, 136367311, 136920334, 137276025, 138024085, 144116035, 152043775, 152258151, 152344200, 160646988, 160657210, 160832411, 162011394, 162038072, 162205111, 163206398, 163397661, 163642948, 165246676, 172919057, 178101884, 180386997, 189622860, 198975457, 223596973, 223685701, 226649713, 242780965, 251971216, 252160402, 252451445, 252543313
|
| Target and Pathway |
| Target(s) |
AKT3 protein kinase |
Target Info |
Modulator |
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Chemokine signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Sphingolipid signaling pathway
|
|
mTOR signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Apoptosis
|
|
Adrenergic signaling in cardiomyocytes
|
|
VEGF signaling pathway
|
|
Osteoclast differentiation
|
|
Focal adhesion
|
|
Tight junction
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Platelet activation
|
|
Toll-like receptor signaling pathway
|
|
Jak-STAT signaling pathway
|
|
T cell receptor signaling pathway
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
TNF signaling pathway
|
|
Neurotrophin signaling pathway
|
|
Cholinergic synapse
|
|
Dopaminergic synapse
|
|
Insulin signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Glucagon signaling pathway
|
|
Regulation of lipolysis in adipocytes
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Carbohydrate digestion and absorption
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Hepatitis C
|
|
Hepatitis B
|
|
Measles
|
|
Influenza A
|
|
HTLV-I infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
Colorectal cancer
|
|
Renal cell carcinoma
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
Chronic myeloid leukemia
|
|
Acute myeloid leukemia
|
|
Small cell lung cancer
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancer
|
|
NetPath Pathway
|
TSH Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Apoptosis signaling pathway
|
|
EGF receptor signaling pathway
|
|
Endothelin signaling pathway
|
|
FGF signaling pathway
|
|
Huntington disease
|
|
Hypoxia response via HIF activation
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Interleukin signaling pathway
|
|
PI3 kinase pathway
|
|
T cell activation
|
|
p53 pathway
|
|
Ras Pathway
|
|
p53 pathway by glucose deprivation
|
|
p53 pathway feedback loops 2
|
|
Pathway Interaction Database
|
S1P3 pathway
|
|
Class I PI3K signaling events mediated by Akt
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5196). |
|---|
| REF 2 | ClinicalTrials.gov (NCT00666081) Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies. U.S. National Institutes of Health. |
|---|
